Johnson & Johnson has the first commercial Varipulse case in Canada

Johnson & Johnson MedTech

(NYSE:JNJ)
+
today announced the first completed commercial case of its Varipulse platform in Canada.

The company said in a post on LinkedIn that doctors at the Ottawa Heart Institute had completed the first commercial case using Varipulse. J&J said the procedure represents “a significant advance” in treating atrial fibrillation using pulsed field ablation (PFA) technology.

“A big thank you to the Ottawa Heart Institute for partnering in bringing this groundbreaking treatment to Canada,” the company wrote. “Together, we are committed to advancing the treatment of cardiac arrhythmias and helping people with this condition live the life they want.”

The Varipulse system consists of the Varipulse catheter, a multi-electrode catheter with a variable loop. The platform also includes the TruPulse generator and the Carto 3 3D cardiac mapping system. The Carto integration enables an intuitive and reproducible workflow with real-time visualization and feedback mechanisms.

Varipulse enables isolation of pulmonary veins with the versatility of a catheter loop, a simple generator user interface, and an intuitive mapping system. It also has personals and PF tagging mechanisms.

Johnson & Johnson MedTech submitted Varipulse for FDA approval in late March. If approved, Varipulse would be the third FDA-approved PFA system for the treatment of atrial fibrillation, following Medtronic and Boston Scientific.